Gastric adenocarcinoma, a prevalent type of stomach cancer, remains a significant focus in cancer research. Advances in molecular biology have shed light on the genetic mutations and pathways driving this malignancy, leading to the identification of key biomarkers and potential therapeutic targets. Research emphasizes the importance of early detection, with novel non-invasive screening methods, such as liquid biopsies, showing promise in identifying circulating tumor DNA. Immunotherapy, particularly checkpoint inhibitors, is emerging as a potent treatment strategy, offering hope for improved survival rates. Additionally, precision medicine, which tailors treatment based on an individual’s genetic profile, is revolutionizing the management of gastric adenocarcinoma, paving the way for more effective and personalized therapeutic approaches.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China